

In response to the Advisory Action of March 15, 2004 in the above-identified application, please amend the application as follows:

**IN THE SPECIFICATION**

Page 1, lines 18-19, please insert the following:

X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub>, X<sub>4</sub>, same or different, are a group chosen among:

-CONR-, -NRCO-, -CH<sub>2</sub>-NR-, -NR-CH<sub>2</sub>- where R is H, C<sub>1-3</sub> alkyl, or benzyl;

Page 1, lines 22-27, please insert the following:

-(CH<sub>2</sub>)<sub>r</sub> Ar<sub>1</sub> where r is 0, 1 or 2 and Ar is an aromatic group chosen among ben[e]zene, naphthalene, thiophene, benzothiophene, pyridine, quinoline, indole, furan, benzofuran, thiazole, benzothiazole, imidazole, benzoimidazole, possibly substituted with up to 2 substituents chosen among C<sub>1-3</sub> alkyl, C<sub>1-3</sub> haloalkyl, C<sub>1-3</sub> alkyloxy [and], C<sub>2-4</sub> amino-alkyloxy, halogens, OH, NH<sub>2</sub>, CN[,] and NR<sub>6</sub>R<sub>7</sub>, where R<sub>6</sub> and R<sub>7</sub>, are the same or different, and are H or C<sub>1-3</sub> alkyl,

At page 5, lines 15-20, please insert:

R<sub>9</sub> is a group chosen among: 4-tetrahydropyranyl, 4-tetraiodothiopyranyl

4-tetrahydrothiopyranyl, 1-oxotetraiodothiopyran-4-yl

1-oxotetrahydrothiopyran-4-yl, 1,1 dioxo-tetrahydrothiopyran-4-yl, N-methyl-4-

piperidinyl, N-methanesulfonyl-4-piperidinyl, N-aminosulfonyl-4-piperdanyl, or R<sub>8</sub> and R<sub>9</sub> together with the N atom to which they are linked represent N-methyl-piperazinyl, N-acetyl-piperazinyl, piperazinyl, N-methanesulfonyl-piperazinyl.

At page 6, lines 13-18, please insert:

xii) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Phe(4-CF<sub>3</sub>)-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

xiii) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Ala(4-pyridyl)-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

xiv) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Ala(3-pyridyl)-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

Page 7, lines 1-5, please insert:

Among the compounds of formula (I) wherein R, R[1]<sub>1</sub>, R[2]<sub>2</sub>, R[3]<sub>3</sub>, f, m are as hereabove defined preferred are also those wherein:

R<sub>4</sub> represents a group NR<sub>8</sub>R<sub>9</sub>, where R<sub>8</sub> is H and R[9]<sub>9</sub> is chosen among:

methanesulfonyl, tosyl, a group (CH<sub>2</sub>)<sub>2</sub>[g]<sub>g</sub>-R<sub>10</sub> wherein g is 1, or 2 and R<sub>10</sub> is chosen among: morpholine, furan, or CN.

Page 7, lines 23-29, please insert:

Another preferred selection of the compound of formula (I) wherein R, R[1]<sub>1</sub>, R[2]<sub>2</sub>, R[3]<sub>3</sub>, f, m are as previously defined, those wherein:

R[4]<sub>4</sub> represents a group -N(R<sub>11</sub>)CO(CH<sub>2</sub>)<sub>h</sub>-R<sub>12</sub> wherein R<sub>11</sub> is H, h is 0 or 1, and R[12]<sub>12</sub> is chosen among. : 1-tetrazolyl, 5-mercaptop-tetrazol-1-yl, 1-triazolyl, furanyl, thiophenyl, morpholine, 4-hydroxy-piperidine, 4-carboxyamido-piperidine, 3-hydroxypyrrolidine,

2-hydroxymethylpyrrolidine, 4-methyl-piperazine, 4-aminosulfonyl-piperazine, 1-oxo-thiomorpholine, 4-hydroxy-cyclohexan-1-yl-amino.

At page 9, lines 7-8, please insert:

Another preferred selection of compounds of formula (I) wherein R, R[1]<sub>1</sub>, R[2]<sub>2</sub>, R[3]<sub>3</sub>, f, m are as above defined are those wherein:

At page 9, lines 9-10, please insert:

R[4]<sub>4</sub> is a group COR<sub>13</sub> where R<sub>13</sub> is a group chosen among: morpholine and 4-(hydroxyethoxyethyl)-piperazine.

At page 10, lines 26-31, please insert:

EXAMPLE 1: cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

(compound of general formula I wherein X<sub>1</sub> = X<sub>2</sub> = X[3]<sub>3</sub> = X<sub>4</sub> = -CO-NH-; R<sub>1</sub> = -CH<sub>2</sub>-(indol-3-yl); R<sub>2</sub> = R<sub>3</sub> = -CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>; R[4]<sub>4</sub> = (4-tetrahydropyranyl)amino; m = 0, f = 1; the carbon atoms C-R<sub>1</sub> and C-R<sub>2</sub> have configuration S, while C-R<sub>3</sub> and C-R<sub>4</sub> have configuration R).

At page 11, lines 2-5, please insert:

(compound of formula (I) wherein: X<sub>1</sub> = X<sub>2</sub> = X[3]<sub>3</sub> = X<sub>4</sub> = -CO-NH-; R<sub>1</sub> = -CH<sub>2</sub>-(indol-3-yl); R<sub>2</sub> = R<sub>3</sub> = -CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>; R<sub>4</sub> = -NH<sub>2</sub>; m = 0, f = 1; the carbon atoms C-R<sub>1</sub> and C-R<sub>2</sub> have configuration S, while C-R<sub>3</sub> and C-R<sub>4</sub> have configuration R) is used. The compound A is prepared as follow:

At page 11, lines 24-30, please insert:

c) Synthesis of Boc-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub><sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>-NH-Z]

To a solution of Boc-Trp-Phe-OH (1.19 g, 2.63 mmoli) in anhydrous DMF (10 ml) (R)-1-benzyl-2-(benzyloxycarbonylamino)ethylamine (750 mg), PyBOP (1.37 g) e DIEA (0.9 ml) were added under nitrogen. The reaction mixture was left under stirring for a

night at room, added with AcOEt (80 ml), washed with HCl 1N (3 x 30 ml), Na<sub>2</sub>CO<sub>3</sub> 5% (3 x 30 ml) and H<sub>2</sub>O (30 ml). The organic phase was evaporated under vacuum at 30°C, giving 1.8 g of ivory colored solid residue.

At page 14, lines 9-13, please insert:

EXAMPLE 2: cyclo{Suc[1-(S)-(4-tetrahydropyranyl)amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

(compound of general formula (I) wherein C-R[4]<sub>4</sub> has S configuration, R[4]<sub>4</sub> is (4-tetrahydropyranyl)amino and the other substituents are as described for Compound A).

At page 14, lines 18-23, please insert:

EXAMPLE 3: cyclo{Suc[1-(R)-(1-methyl-piperidin-4-yl)amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

(compound of general formula I wherein R[4]<sub>4</sub> is (1-methyl-piperidin-4-yl)amino and the other substituents are as described for Compound A).

The compound is prepared as in example 1 but using as reagent 1-methyl-4-piperidone.

At page 15, lines 2-6, please insert:

(compound of formula I wherein R[4]<sub>4</sub> is (4-tetrahydrothiopyranyl)amino and the other substituents are as described for compound A).

The compound is prepared according to Example 1 but using as reagent tetrahydro-thiopyran-4-one.

At page 15, lines 7-11, please insert:

EXAMPLE 5: cyclo{Suc[1-(R)-(1-oxo-tetrahydrothiopyran-4-yl)amino]-Trp-Phe-[  
[(R)NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

(compound of general formula I wherein R[4]<sub>4</sub> is (1-oxo-4-tetrahydrothiopyranyl)amino  
and the other substituents are the same of Compound A).

At page 15, lines 16-20, please insert:

EXAMPLE 6: cyclo{Suc[1-(R)-(1,1-dioxo-tetrahydrothiopyran-4-yl)amino]-Trp-  
Phe[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

(compound of general formula I wherein R[4]<sub>4</sub> is (1,1-dioxo-4-  
tetrahydrothiopyranyl)amino and the other substituents are the same of  
Compound A).

At page 15, lines 25-29, please insert:

EXAMPLE 7: cyclo{Suc[1-(R)-N-methyl-N-(4-tetrahydropyranyl)amino]-Trp-Phe-[(R)-  
NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

(compound of general formula I wherein R[4]<sub>4</sub> is N-methyl-N-(4-  
tetrahydropyranyl)amino and the other substituents are the same of Compound A).

At page 16, lines 8-12, please insert:

EXAMPLE 8: cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Tyr-[(R)-NH-  
CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

(compound of general formula I wherein cui R<sub>2</sub> = 4-hydroxybenzyl, R[4]<sub>4</sub>  
=(4-tetrahydropyranyl)amino and the other substituents are as defined for Compound A).

At page 16, lines 17-21, please insert:

EXAMPLE 9: cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Phe(4-F)-[(R)-NH-

CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

(compound of general formula I wherein cui R<sub>2</sub> =4-fluorobenzyl, R[4]<sub>4</sub>

=(4-tetrahydropyranyl)amino and the other substituents are as defined for Compound A).

At page 16, lines 26-30, please insert:

EXAMPLE 10: cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Phe(3,5-F)-[(R)-NH-

CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

(compound of general formula I wherein cui R<sub>2</sub> = 3,5-difluorobenzyl, R[4]<sub>4</sub>

=(4-tetrahydropyranyl)amino and the other substituents are as defined for Compound A).

At page 17, lines 5-14, please insert:

EXAMPLE 11: cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Phe(4-CN)-[(R)-NH-

CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

To 377 mg of Boc-(S)-4-ciano-phenylalanine, solved in 8 ml of DMF, HOBt (470 mg),

EDCI.HCl (330 mg) and 630 mg of (R)-1-benzyl-2-(N-

fluorenylmethyloxycarbonylamino)ethylamina trifluoroacetate (prepared according to

Example 1(b)), solved in 8 ml of DMF are added in the given order. DIEA (0.38 ml) is

added drop by drop maintaining under stirring for 3 h. The solution is dried and the

residue is treated with citric acid 105 and water; the precipitated solid is filtered, washed

with water, NaHCO<sub>3</sub> 5%, water and dried. The obtained solid (790 mg) is suspended

in dichloromethane (6.5 ml).

At page 18, lines 26-29, please insert:

EXAMPLE 12: cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Phe(4-CF<sub>3</sub>)-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

(compound of formula I wherein R<sub>2</sub> = (4-trifluoromethyl)benzyl, R[4]<sub>4</sub> = (4-tetrahydropyranyl)amino and the other substituents are as in Compound A.

At page 19, lines 3-9, please insert:

EXAMPLE 13: cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Ala(4-pyridyl)-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

(compound of formula I wherein R<sub>2</sub> = 4-pyridylmethyl, R[4]<sub>4</sub> = (4-tetrahydropyranyl)amino and the other substituents are as in Compound A.

At page 19, lines 11-14, please insert:

EXAMPLE 14: cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Ala(3-pyridyl)-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

(compound of general formula I wherein R<sub>2</sub> = 3-pyridylmethyl, R[4]<sub>4</sub> = (4-tetrahydropyranyl) and the other substituents are as in Compound A.

At page 19, lines 19-24, please insert:

EXAMPLE 15: cyclo{Suc[1-(R)-(1-methylsulfonyl-piperidin-4-yl)amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

(compound of formula I wherein R[4]<sub>4</sub> = (1-methylsulfonyl)piperidin-4-yl)amino and the other substituents are as in Compound A).

At page 19, lines 27-30, please insert:

EXAMPLE 16: cyclo{Suc[1-(R)-(1-aminosulfonyl-piperidin-4-yl)amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

(compound of general formula I wherein R[4]<sub>4</sub> = (1-aminosulfonyl)piperidin-4-yl)amino and the other substituents are as in Compound A).

At page 20, lines 5-8, please insert:

EXAMPLE 17: cyclo{Suc[1-(R)-(piperazin-1-yl)]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

(compound of formula I wherein R[4]<sub>4</sub> = piperazin-1-yl and the other substituents are as in Compound A.

At page 20, lines 20-23, please insert:

EXAMPLE 18: cyclo{Suc[1-(R)-4-methyl-piperazin-1-yl]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

(compound of formula I wherein R[4]<sub>4</sub> = 4-methyl-piperazin-1-yl and the other substituents are as described in Compound A)

At page 21, lines 2-5, please insert:

EXAMPLE 19: cyclo{Suc[1-(R)-4-acetyl-piperazin-1-yl]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

(compound of general formula I wherein R[4]<sub>4</sub> = 4-acetyl-piperazin-1-yl and the other substituents are as described in Compound A)

At page 21, lines 15-18, please insert:

EXAMPLE 20: cyclo{Suc[1-(R)-(4-methanesulfonyl-piperazin-1-yl)]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

(compound of general formula I wherein R[4]<sub>4</sub> = 4-methanesulfonyl-piperazin-1-yl and the other substituents are as described in Compound A).

At page 21, lines 28-31, please insert:

EXAMPLE 21: cyclo{-Suc[1-(S)-methanesulfonylamino]-Trp-Phe-[(R)-NH-

CH(CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>-NH]}

(compound of general formula I wherein C-R[4]<sub>4</sub> has S-configuration, R[4]<sub>4</sub> is methanesulfonylamino and the other substituents are as described in compound A)

At page 22, lines 1-8, please insert:

To a solution of 60 mg of the isomer of Compound A having S-configuration at the C-R[4]<sub>4</sub>, prepared as described in Example 1(a)-1(h), in 1 ml DMF, at 0°C, 24 ml of N-methylmorpholine and 10 ml of methanesulfonylchloride are added; the solution is left under stirring for 2 and half h. The reaction mixture is concentrated under vacuum, diluted with ethylacetate and washed with an aqueous solution of citric acid (10%), water, saturated solution of NaHCO<sub>3</sub> and water in the given order. After drying on Na<sub>2</sub>SO<sub>4</sub> and evaporation of the solvent the product is isolated by preparative HPLC.

At page 22, lines 16-19, please insert:

EXAMPLE 22: cyclo{Suc[1-(R)-methanesulfonylamino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-

C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

(compound of general formula I wherein R[4]<sub>4</sub> is methanesulfonylamino and the other substituents are as described for Compound A)

At page 22, lines 25-31, please insert:

EXAMPLE 23: cyclo{Suc[1-(S)-(4-methylbenzen)sulfonylamino]-Trp-

Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

(compound of general formula I wherein C-R[4]<sub>4</sub> has S-configuration, R[4]<sub>4</sub> is

(4-methylbenzen)sulfonylamino and the other substituents are as described for Compound A)

At page 22, lines 30-31, please insert:

As starting compound the isomer of Compound A having S-configuration at the C-R[4]<sub>4</sub> is used.

At page 23, lines 2-6, please insert:

EXAMPLE 24: cyclo{Suc[1-(R)-(4-methylbenzen)sulfonylamino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

(compound of formula I wherein R[4]<sub>4</sub> is (4-methylbenzen)sulfonylamino and the other substituents are as described for Compound A)

At page 23, lines 11-15, please insert:

EXAMPLE 25: cyclo{Suc[1-(S)-(2-(4-morpholino)ethylamino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

(compound of general formula I wherein C-R[4]<sub>4</sub> has S-configuration, R[4]<sub>4</sub> is 2-(4-morpholino)ethylamino and the other substituents are as described for Compound A)

At page 23, lines 26-29, please insert:

EXAMPLE 26: cyclo{Suc[1-(R)-(2-(4-morpholino)ethylamino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

(compound of general formula I wherein R[4]<sub>4</sub> is 2-(4-morpholino)ethylamino and the other substituents are as described for Compound A)

At page 24, lines 2-5, please insert:

EXAMPLE 27: cyclo{Suc[1-(R)-(2-furylmethyl)amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

(compound of formula I wherein R[4]<sub>4</sub> is (2-furylmethyl)amino and the other substituents are as described for Compound A)

At page 24, lines 15-18, please insert:

EXAMPLE 28: cyclo{Suc[1-(R)-c[i]yanomethylamino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

(compound of general formula I wherein R[4]<sub>4</sub> is c[i]yanomethylamino and the other substituents are as described for Compound A)

At page 25, lines 1-2, please insert:

(compound of general formula I wherein R[4]<sub>4</sub> is 2-(4-morpholinoacetyl)amino and the other substituents are as described for Compound A)

At page 25, lines 16-20, please insert:

EXAMPLE 30: cyclo{Suc[1-(S)-2-(4-morpholinoacetyl)amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

(compound of general formula I wherein R[4]<sub>4</sub> is 2-(4-morpholinoacetyl)amino, C-R[4]<sub>4</sub> has S-configuration and the other substituents are as described for Compound A)

At page 25, lines 28-32, please insert:

EXAMPLE 31: cyclo{Suc[1-(S)-(2-tetrazol-1-yl)acetylamino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

(compound of general formula I wherein C-R[4]<sub>4</sub> has S-configuration, R[4]<sub>4</sub> is (2-tetrazol-1-yl)acetylamino and the other substituents are as described for Compound A)

At page 26, lines 1-2, please insert:

As starting compound the isomer of compound A having S-configuration at C-R[4]<sub>4</sub> is used.

At page 26, lines 8-11, please insert:

EXAMPLE 32: cyclo{Suc[1-(R)-(2-tetrazol-1-yl)acetylamino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

(compound of general formula I wherein R[4]<sub>4</sub> is (2-tetrazol-1-yl)acetylamino and the other substituents are as described for Compound A)

At page 26, lines 13-17, please insert:

EXAMPLE 33: cyclo{Suc[1-(S)-(2-(5-mercaptop-tetrazol-1-yl)acetylamino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

(compound of general formula I wherein C-R[4]<sub>4</sub> has S-configuration, R[4]<sub>4</sub> is (2-(5-mercaptop-tetrazol-1-yl)acetylamino and the other substituents are as described for Compound A)

At page 26, lines 18-19, please insert:

As starting compound the isomer of Compound A having S-configuration at C-R[4]<sub>4</sub> is used.

At page 26, lines 25-29, please insert:

EXAMPLE 34: cyclo{Suc[1-(R)-2-([1,2,4]triazol-1-yl)acetylamino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

(compound of general formula I wherein R[4]<sub>4</sub> is 2-([1,2,4]triazol-1-yl)acetylamino and the other substituents are as described for Compound A)

At page 27, lines 1-4, please insert:

EXAMPLE 35: cyclo{Suc[1-(R)-(furan-2-yl)carbonylamino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

(compound of general formula I wherein R[4]<sub>4</sub> is (furan-2-yl)carbonylamino and the other substituents are as described for Compound A)

At page 27, lines 10-13, please insert:

EXAMPLE 36: cyclo{Suc[1-(R)-2-(thiophen-3-yl)acetylarnino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

(compound of general formula I wherein R[4]<sub>4</sub> is 2-(thiophen-3-yl)acetylarnino and the other substituents are as described for Compound A)

At page 27, lines 18-21, please insert:

EXAMPLE 37: cyclo{Suc[1-(R)-(4-morpholino)carbonylarnino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

(compound of general formula I wherein R[4]<sub>4</sub> is (4-morpholino)carbonylarnino and the other substituents are as described for Compound A)

At page 27, lines 29-31, bridging page 28 line 1, please insert:

EXAMPLE 38: cyclo{Suc[1-(R)-2-(4-hydroxy-piperidin-1-yl)acetylarnino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

(compound of general formula I wherein R[4]<sub>4</sub> is 2-(4-hydroxy-piperidin-1-yl)acetylarnino and the other substituents are as described for Compound A)

At page 28, lines 6-10, please insert:

EXAMPLE 39: cyclo{Suc[1-(R)-2-(4-aminocarbonyl-piperidin-1-yl)acetylarnino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

(compound of general formula I wherein R[4]<sub>4</sub> is 2-(4-aminocarbonyl-piperidin-1-yl)acetylarnino and the other substituents are as described for Compound A)

At page 28, lines 15-20, please insert:

EXAMPLE 40: cyclo{Suc[1-(R)-2-(3-hydroxy-pyrrolidin-1-yl)acetylarnino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

(compound of general formula I wherein R[4]<sub>4</sub> is 2-(3-hydroxy-pyrrolidin-1-yl)acetyl amino and the other substituents are as described for Compound A)

At page 29, lines 2-3, please insert:

(compound of general formula I wherein R[4]<sub>4</sub> is 2-(4-methyl-piperazin-1-yl)acetyl amino and the other substituents are as described for Compound A)

At page 29, lines 8-19 and 20-27, please insert:

EXAMPLE 43: cyclo{Suc[1-(R)-2-(4-methyl-piperazin-1-yl)carbonyl amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

(compound of general formula I wherein R[4]<sub>4</sub> is 2-(4-methyl-piperazin-1-yl)carbonyl amino and the other substituents are as described for Compound A)

A solution of 40 mg of compound A, obtained as described in EXAMPLE 1(a)-1(h), and 400 µl of DIPEA in THF (0.5 ml), is added, under nitrogen, to a solution of 27 mg of 4-methyl-1-piperazinocarbonyl chloride (prepared as described in C. Jorand-Lebrun et al., Synth. Commun. (1998), 28, 1189) in 0.5 ml of dichloromethane. The solution is stirred for 2 h at room temperature, dried and purified by HPLC (Method P7).

HPLC (Method A2): rt = 11.8 min.

MS: m/z = 707.2 (MH<sup>+</sup>).

EXAMPLE 44: cyclo{Suc[1-(R)-2-(4-aminosulfonyl-piperazin-1-yl)acetyl amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

(compound of general formula I wherein R[4]<sub>4</sub> is 2-(4-aminosulfonyl-piperazin-1-yl)acetyl amino and the other substituents are as described for Compound A)

The compound was prepared according to EXAMPLE 29 but using as reagent 2-(4-aminosulfonyl-piperazin-1-yl)acetic acid.

HPLC (Method A2):  $t_r = 12.5$  min.

MS:  $m/z = 786.3$  ( $MH^+$ )

At page 29, lines 26-31, please insert:

EXAMPLE 45: cyclo{Suc[1-(R)-2-(1-oxo-thiomorpholin-4-yl)acetylamino]-Trp-Phe-  
[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

(compound of general formula I wherein R[4]<sub>4</sub> is 2-(1-oxo-thiomorpholin-4-yl)acetylamino and the other substituents are as described for Compound A)

At page 30, lines 5-9, please insert:

EXAMPLE 46: cyclo{Suc[1-(R)-2-(*trans*-4-hydroxy-cyclohexan-1-yl-amino)acetylamino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

(compound of general formula I wherein R[4]<sub>4</sub> is 2-(*trans*-4-hydroxy-cyclohexan-1-yl-amino)acetylamino and the other substituents are as described for Compound A).

At page 30, lines 14-19, please insert:

EXAMPLE 47: cyclo{Suc[1-(4-morpholino)carbonyl]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

(compound of general formula I wherein : X<sub>1</sub> = X<sub>2</sub> = X<sub>3</sub> = X<sub>4</sub> = -CO-NH-; R<sub>1</sub> = -CH<sub>2</sub>- (indol-3-yl); R<sub>2</sub> = R<sub>3</sub> = -CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>; R[4]<sub>4</sub> = (4-morpholino)carbonyl; m = 0, f = 1; the C-R<sub>1</sub> and C-R<sub>2</sub> carbon atoms have S-configuration, while C-R<sub>3</sub> has R-configuration)

At page 31, lines 21-28, please insert:

To a solution of 200 mg of H-Trp-Phe-{(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>-NH-[2-(4-nitro-benzyloxycarbonyl)]-1-succinic acid in DMF (10 ml), under nitrogen at 0°C, PyBOP (160 mg) and TEA (108 µl) were added; the solution was left under stirring at room temperature for 2 hours and thereafter sampled by HPLC. The solvent was evaporated and the residue was solved in ethylacetate. The organic phase was washed with

KHSO<sub>4</sub> aq. 5%, NaHCO<sub>3</sub> aq. 5%, brine and was dried on anhydrous sodium sulfate.

After filtration and evaporation of the solvent 180 mg of a residue were obtained.

At page 32, lines 4-9, please insert:

The compound cyclo{Suc[1-(4-nitro-benzyloxycarbonyl)-Trp-Phe-[(R)NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>-NH]} “slow moving” (50 mg) was added to a mixture 1:1 of water/isopropanole (2 ml) containing K[2]<sub>2</sub>CO[3]<sub>3</sub> (17 mg). The reaction mixture was reacted for 24 h at room temperature, concentrated, diluted with water and extracted with ethylacetate to eliminate the unreacted product.

At page 32, lines 19-27, please insert:

The compound cyclo {Suc[1-(4-nitro-benzyloxycarbonyl)-Trp-Phe-[(R)-NH-CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>]-CH<sub>2</sub>-NH]} “slow moving” (50 mg) was added to a mixture 1:1 of water/isopropanole (2 ml) containing K[2]<sub>2</sub>CO[3]<sub>3</sub> (17 mg). The reaction mixture was extracted with ethylacetate to eliminate the unreacted product. The aqueous phase was acidified with HCl 1N up to the formation of a white suspension and extracted with ethylacetate. The organic phase of the second extraction was dried on anhydrous sodium sulfate and evaporated to give 18 mg of a white solid. The product was purified by preparative HPLC (Method P8).

At page 33, lines 13-17, please insert:

EXAMPLE 48: cyclo{Suc[1-(4-hydroxyethyloxyethyl-piperazin-1-yl)carbonyl]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}


(compound of general formula I wherein R[4]<sub>4</sub> is (4-hydroxyethyloxyethyl-piperazin-1-yl)carbonyl and the other substituents are as described in EXAMPLE 47)

HPLC (Method A2):  $t_R = 11.9$  min.

IN THE CLAIMS

21. (Currently Amended) Monocyclic compounds of formula (I)

wherein:



X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub>, X<sub>4</sub> are the same or different, and are selected from the group consisting of -CONR-, -NRCO-, -CH<sub>2</sub>-NR-, and -NR-CH<sub>2</sub>- where R is selected from the group consisting of H, C<sub>1-3</sub> alkyl, and benzyl;

f and m are the same or different, and are a number selected from the group consisting of 0, 1 and 2;

R<sub>1</sub> and R<sub>2</sub>, are the same or different, and represent:

-(CH<sub>2</sub>)<sub>r</sub>Ar where r is 0, 1 or 2 and Ar is an aromatic group selected from the group consisting of benzene, naphthalene, thiophene, benzothiophene, pyridine, quinoline, indole, furan, benzofuran, thiazole, benzothiazole, imidazole, benzimidazole, optionally substituted with up to 2 substituents selected from the group consisting of C<sub>1-3</sub> alkyl, C<sub>1-3</sub> haloalkyl, C<sub>1-3</sub> alkyloxy, C<sub>2-4</sub> amino-alkyloxy, halogens, OH, NH<sub>2</sub>, CN, and NR<sub>6</sub>R<sub>7</sub>, where R<sub>6</sub> and R<sub>7</sub>, same or different, are H or C<sub>1-3</sub> alkyl,

R<sub>3</sub> is-(CH<sub>2</sub>)<sub>r</sub>Ar<sub>1</sub> where r is 0, 1 or 2 and Ar<sub>1</sub> is an aromatic group selected from the group consisting of benzene, naphthalene, thiophene, benzothiophene, pyridine, quinoline, indole, furan, benzofuran, thiazole, benzothiazole, imidazole, and benzimidazole,

optionally substituted with up to 2 groups selected from the group consisting of C<sub>1-3</sub> alkyl, C<sub>1-3</sub> haloalkyl, C<sub>1-3</sub> alkyloxy, C<sub>2-4</sub> amino-alkyloxy, halogens, OH, NH<sub>2</sub>, and NR<sub>6</sub>R<sub>7</sub>, where R<sub>6</sub> and R<sub>7</sub>, same or different, are H or C<sub>1-3</sub> alkyl,  
R<sub>5</sub> is H,  
R<sub>4</sub> is -NR<sub>8</sub>R<sub>9</sub>; -N(R<sub>11</sub>)CO(CH<sub>2</sub>)<sub>h</sub>R<sub>12</sub>; or -COR<sub>13</sub>; where R<sub>8</sub> is H or C<sub>1-3</sub> alkyl; h is 0, 1, 2 or 3; and R<sub>9</sub> is selected from the group consisting of methanesulfonyl, tosyl, tetrahydropyranyl, tetrahydrothiopyranyl optionally mono or di-substituted by oxygen on the S atom, piperidyl, optionally substituted on the N-atom by a C<sub>1-3</sub> alkyl, C<sub>1-3</sub> acyl, aminosulfonyl, or methanesulfonyl; or a group -(CH<sub>2</sub>)<sub>g</sub>R<sub>10</sub> where g is 1,2, or 3 and R<sub>10</sub> is selected from the group consisting of morpholine, furan and CN;  
or R<sub>8</sub> and R<sub>9</sub> together with the N atom to which they are linked form a piperazine optionally substituted at the other N atom by a C<sub>1-3</sub> alkyl, C<sub>1-3</sub> acyl or methanesulfonyl;  
R<sub>11</sub> is H or C<sub>1-3</sub> alkyl; h is 0, 1, 2 or 3; and R<sub>12</sub> is selected from the group consisting of morpholine, pyrrolidine optionally substituted with a hydroxy or hydroxymethyl, piperidine optionally substituted with a 4-hydroxy or 4-carboxyamido, piperazine optionally substituted on the other N-atom by C<sub>1-3</sub> alkyl, triazole, tetrazole, 5-mercaptop-tetrazole, furan, thiophene, and thiomorpholine, optionally mono or di-oxygenated on the S-atom;  
R<sub>13</sub> is a member selected from the group consisting of morpholine and piperazine optionally substituted by a C<sub>2-6</sub> alkyl containing one or more hydroxy groups;  
their enantiomers and mixtures thereof, their diastereoisomers, and their pharmaceutically acceptable salts.

22. (Previously Amended) Compound according to Claim 21 wherein:

f is 1

m is 0

X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub>, X<sub>4</sub>, are the same or different and are a member selected from the group consisting of -CONR- and -NRCO-,

where R is H or methyl,

R<sub>1</sub> and R<sub>2</sub> are the same or different, are:

-CH<sub>2</sub>Ar wherein Ar is an aromatic group selected from the group consisting of benzene, pyridine, indole, optionally substituted with up to two substituents selected from the group consisting of C<sub>1-3</sub> alkyl, C<sub>1-3</sub> haloalkyl, C<sub>1-3</sub> alkyloxy, C<sub>2-4</sub> amino alkyloxy, halogens, OH, NH<sub>2</sub>, CN, and NR<sub>6</sub>R<sub>7</sub>, where R<sub>6</sub> and R<sub>7</sub>, same or different, and are H or C<sub>1-3</sub> alkyl;

R<sub>3</sub> is -CH<sub>2</sub>Ar<sub>1</sub> wherein Ar<sub>1</sub> is an aromatic group selected from the group consisting of alpha naphthyl, beta naphthyl, phenyl, and phenyl substituted with up to two substituents selected from the group consisting of C<sub>1-3</sub> alkyl, C<sub>1-3</sub> haloalkyl, C<sub>1-3</sub> alkyloxy, halogens, OH, and NH<sub>2</sub>.

23. (Previously Amended) Compounds according to Claim 22 wherein:

- X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub>, X<sub>4</sub> are -CONH-,

- R<sub>1</sub> is indol-3-yl-methyl

- R<sub>2</sub> is phenyl-methyl optionally substituted with up to two substituents selected from the group consisting of chlorine, fluorine, CF<sub>3</sub>, OH and CN; or is selected from the group consisting of 3-pyridyl-methyl and 4-pyridyl-methyl;

- R<sub>3</sub> is benzyl.

24. (Previously Added) Compounds according to claim 23 wherein:

R<sub>4</sub> is a group NR<sub>8</sub>R<sub>9</sub> wherein:

R<sub>8</sub> is H or methyl;

R<sub>9</sub> selected from the group consisting of 4-tetrahydropyranyl, 4-tetrahydrothiopyranyl, 1-oxo-tetrahydrothiopyran-4-yl, 1,1-dioxo-tetrahydrothiopyran-4-yl, N-methyl-4-piperidinyl, N-methanesulfonyl-4-piperidinyl, and N-aminosulfonyl-4-piperidinyl,

or R<sub>8</sub> and R<sub>9</sub> together with the N atom to which they are linked represent N-methyl-piperazinyl, N-acetyl-piperazinyl or N-methanesulfonyl-piperazinyl.

25. (Currently Amended) Compounds according to Claim 24 represented by:

- i) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}
- ii) cyclo{Suc[1-(S)-(4-tetrahydropyranyl)amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}
- iii) cyclo{Suc[1-(R)-(1-methyl-piperidin-4-yl)amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}
- iv) cyclo{Suc[1-(R)-(4-tetrahydrothiopyranyl)amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}
- v) cyclo{Suc[1-(R)-(1-oxo-tetrahydrothiopyran-4-yl)amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}
- vi) cyclo{Suc[1-(R)-(1,1-dioxo-tetrahydrothiopyran-4-yl)amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

- vii) cyclo{Suc[1-(R)-N-methyl-N-(4-tetrahydropyranyl)amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}
- viii) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Tyr-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}
- ix) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Phe(4-F)-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}
- x) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Phe(3,5-F)-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}
- xi) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Phe(4-CN)-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}
- xii) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Phe(4-CF[3]<sub>2</sub>)-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}
- xiii) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Ala(4-pyridyl)-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}
- xiv) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Ala(3-pyridyl)-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}
- xv) cyclo{Suc[1-(R)-(1-methylsulfonyl-piperidin-4-yl)amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}
- xvi) cyclo{Suc[1-(R)-(1-aminosulfonyl-piperidin-4-yl)amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}
- xvii) cyclo{Suc[1-(R)-4-methyl-piperazin-1-yl]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}
- xviii) cyclo{Suc[1-(R)-4-acetyl-piperazin-1-yl]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]} or

xix) cyclo{Suc[1-(R)-4-methylsulfonyl-piperazin-1-yl]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}.

26. (Previously Amended) Compounds according to Claim 23 wherein:

R<sub>4</sub> represents a group NR<sub>8</sub>R<sub>9</sub>, where R<sub>8</sub> is H and R<sub>9</sub> is methanesulfonyl, tosyl or a group -(CH<sub>2</sub>)<sub>g</sub>R<sub>10</sub>, wherein g is 1 or 2 and R<sub>10</sub> is morpholine, furan, or CN.

27. (Previously Amended) Compounds according to claim 26 represented by:

xx) cyclo{Suc[1-(S)-methylsulfonylamino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

xxi) cyclo{Suc[1-(R)-methylsulfonylamino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

xxii) cyclo{Suc[1-(S)-(4-methylphenyl)sulfonylamino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

xxiii) cyclo{Suc[1-(R)-(4-methylphenyl)sulfonylamino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

xxiv) cyclo{Suc[1-(S)-2-(4-morpholino)ethylamino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

xxv) cyclo{Suc[1-(R)-2-(4-morpholino)ethylamino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

xxvi) cyclo{Suc[1-(R)-(2-furyl)methylamino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

or

xxvii) cyclo{Suc[1-(R)-cyanomethylamino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}.

28. (Currently Amended) Compounds according to claim 23 wherein:

R<sub>4</sub> is a group -N(R<sub>11</sub>)CO(CH<sub>2</sub>)<sub>h</sub>-R<sub>12</sub> wherein R<sub>11</sub> is H, h is 0 or 1, and R<sub>12</sub> is selected from the group consisting of 1-tetrazolyl, 5-mercaptop-tetrazol-1-yl, 1-triazolyl, furanyl,

thiophenyl, morpholine, 4-hydroxy-piperidine, 4-carboxyamido-piperidine, 3-hydroxy-pyrrolidine, 2-hydroxymethylpyrrolidine, 4-methyl-piperazine, and 1-oxo-thiomorpholine[.]

29. (Currently Amended) Compounds according to Claim 28 represented by:
- xxviii) cyclo{Suc[1-(R)-2-(4-morpholino)acetyl amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}
  - xxix) cyclo{Suc[1-(S)-2-(4-morpholino)acetyl amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}
  - xxx) cyclo{Suc[1-(S)-2-(tetrazol-1-yl)acetyl amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}
  - xxxi) cyclo{Suc[1-(R)-2-(tetrazol-1-yl)acetyl amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}
  - xxxii) cyclo{Suc[1-(S)-2-(5-mercaptop-tetrazol-1-yl)acetyl amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}
  - xxxiii) cyclo{Suc[1-(R)-2-([1,2,4]triazol-1-yl)acetyl amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)CH<sub>2</sub>NH]}
  - xxxiv) cyclo{Suc[1-(R)-2-(furanyl)carbonyl amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}
  - xxxv) cyclo{Suc[1-(R)-2-(thiophen-3-yl)acetyl amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}
  - xxxvi) cyclo{Suc[1-(R)-(4-morpholino)carbonyl amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

xxxvii) cyclo{Suc[1-(R)-2-(4-hydroxy-piperidin-1-yl)acetyl amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

xxxviii) cyclo{Suc[1-(R)-2-(4-aminocarbonyl-piperidin-1-yl)acetyl amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

xxxix) cyclo{Suc[1-(R)-2-(3-hydroxy-pyrrolidin-1-yl)acetyl amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

xl) cyclo{Suc[1-(R)-2-(2-(S)-hydroxymethyl-pyrrolidin-1-yl)acetyl amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

xli) cyclo{Suc[1-(R)-2-(4-methyl-piperazin-1-yl)acetyl amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

xlii) cyclo{Suc[1-(R)-2-(4-methyl-piperazin-1-yl)carbonyl amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]} or

xliii) cyclo{Suc[1-(R)-2-(1-oxo-thiomorpholin-4-yl)acetyl amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}.

30. (Previously Amended) Compounds according to Claim 23 wherein:  
R<sub>4</sub> represents a group COR<sub>13</sub> wherein R<sub>13</sub> is morpholine.


31. (Previously Amended) Compounds according to claim 30 represented by: xlvi) cyclo{Suc[1-(4-morpholino)carbonyl]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}.

32. (Previously Added) Pharmaceutical compositions containing as active principle compounds of general formula (I) according to Claim 21 in combination with pharmaceutically acceptable carriers or excipients.

33. (Previously Added) A method for the treatment of the bronchospastic component of asthma, cough, pulmonary irritation, intestinal spasms or local spasms of bladder, ureters during cystitis, kidney infections and colics wherein amounts of 0.1 to 10mg/kg body weight of an active principle represented by compounds of formula (I) according to Claim 21 are administered to the patient.

34. (Currently Amended) Monocyclic compounds of formula (I)

wherein:



X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub>, X<sub>4</sub> are the same or different, and are selected from the group consisting of -CONR-, -NRCO-, -CH<sub>2</sub>-NR-, and -NR-CH<sub>2</sub>- where R is selected from the group consisting of H, C<sub>1-3</sub> alkyl, and benzyl;  
f and m are the same or different, and are a number selected from the group consisting of 0, 1 and 2;

R<sub>1</sub> and R<sub>2</sub>, are the same or different, and represent:

-(CH<sub>2</sub>)<sub>r</sub>Ar where r is 0, 1 or 2 and Ar is an aromatic group selected from the group consisting of benzene, naphthalene, thiophene, benzothiophene, pyridine, quinoline, indole, furan, benzofuran, thiazole, benzothiazole, imidazole, benzoimidazole, optionally substituted with up to 2 substituents selected from the group consisting of C<sub>1-3</sub> alkyl, C<sub>1-3</sub> haloalkyl, C<sub>1-3</sub> alkyloxy, C<sub>2-4</sub> amino-alkyloxy, halogens, OH, NH<sub>2</sub>, CN, and NR<sub>6</sub>R<sub>7</sub>, where R<sub>6</sub> and R<sub>7</sub>, same or different, are H or C<sub>1-3</sub> alkyl,

$R_3$  is  $-(CH_2)_rAr_1$  where  $r$  is 0, 1 or 2 and  $Ar_1$  is an aromatic group selected from the group consisting of benzene, naphthalene, thiophene, benzothiophene, pyridine, quinoline, indole, furan, benzofuran, thiazole, benzothiazole, imidazole, and benzimidazole, optionally substituted with up to 2 groups selected from the group consisting of  $C_{1-3}$  alkyl,  $C_{1-3}$  haloalkyl,  $C_{1-3}$  alkyloxy,  $C_{2-4}$  amino-alkyloxy, halogens, OH, NH<sub>2</sub>, and NR<sub>6</sub>R<sub>7</sub>, where R<sub>6</sub> and R<sub>7</sub>, same or different, are H or  $C_{1-3}$  alkyl,

R<sub>5</sub> is H,

R<sub>4</sub> is  $[-NR_8R_9;]-N(R_{11})CO(CH_2)_hR_{12};$  or  $-COR_{13};$  where R<sub>8</sub> is H or  $C_{1-3}$  alkyl; h is 0, 1, 2 or 3; and R<sub>9</sub> is selected from the group consisting of methanesulfonyl, tosyl, tetrahydropyranyl, tetrahydrothiopyranyl optionally mono or di-substituted by oxygen on the S atom, piperidyl, optionally substituted on the N-atom by a  $C_{1-3}$  alkyl,  $C_{1-3}$  acyl, aminosulfonyl, or methanesulfonyl; or a group  $-(CH_2)_gR_{10}$  where g is 1, 2, or 3 and R<sub>10</sub> is selected from the group consisting of morpholine, furan and CN;

or R<sub>8</sub> and R<sub>9</sub> together with the N atom to which they are linked form a piperazine optionally substituted at the other N atom by a  $C_{1-3}$  alkyl,  $C_{1-3}$  acyl or methanesulfonyl;]

where R<sub>11</sub> is H or  $C_{1-3}$  alkyl; h is 0, 1, 2 or 3; and R<sub>12</sub> is selected from the group consisting of 1-tetrazolyl, 5-mercaptop-tetrazol-1-yl, 1-triazolyl, furanyl, thiophenyl, morpholine, 4-hydroxy-piperidine, 4-carboxyamido-piperidine, 3-hydroxy-pyrrolidine, 2-hydroxymethylpyrrolidine, 4-methyl-piperazine, 4-aminosulfonyl-piperazine, 1-oxo-thiomorpholine and 4-hydroxy-cyclohexan-1-yl-amino; and

[R<sub>13</sub> is a member selected from the group consisting of morpholine and piperazine optionally substituted by a  $C_{2-6}$  alkyl containing one or more hydroxy groups;]

their enantiomers and mixtures thereof, their diastereoisomers, and their pharmaceutically acceptable salts.

35. (Previously Presented) Compounds according to claim 34 represented by:

- i) cyclo{Suc[1-(R)-2-(4-amino sulfonyl-piperazin-1-yl)acetyl amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]} or
- ii) cyclo{Suc[1-(R)-2-(*trans*-4-hydroxy-cyclohexan-1-yl-amino)acetyl amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}.